Management of brain metastases

Current Treatment Options in Neurology

Volumn 12, Issue 4, 2010, Pages 334-346

  Stewart, John G ^a   Sawrie, Stephen M ^a   Bag, Asim ^a   Han, Xiaosi ^a   Fiveash, John B ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; TEMOZOLOMIDE;

BRAIN METASTASIS; BRAIN RADIATION; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DIFFUSION WEIGHTED IMAGING; DOSE RESPONSE; DRUG DOSE REDUCTION; GLIOBLASTOMA; HUMAN; IMAGE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIOSURGERY; REVIEW; RISK ASSESSMENT; SCINTIGRAPHY; SURGICAL APPROACH; SURGICAL TECHNIQUE; SYSTEMIC THERAPY; TREATMENT OUTCOME; WHOLE BRAIN RADIATION THERAPY;

EID: 77956394772     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-010-0074-9     Document Type: Review

References (26)

1. Gaspar L, Scott C, Rotman M, et al.: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997, 37:745-751.
2. Sperduto PW, Chao ST, Sneed PK, et al.: Diagnosisspecific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: A multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2009 Nov 24 (Epub ahead of print). The GPA will replace the RTOG RPA as the standard prognostic index for patients with brain metastases. The revised GPA is disease-specific.
3. Andrews DW, Scott CB, Sperduto PW, et al.: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 2004, 363:1665-1672.
4. DeAngelis LM: Management of brain metastases. Cancer Invest 1994, 12:156-165.
5. Sawrie SM, Guthrie BL, Spencer SA, et al.: Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone. Int J Radiat Oncol Biol Phys 2008, 70:181-186.
6. Aoyama H, Shirato H, Tago M, et al.: Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. JAMA 2006, 295:2483-2491.
7. Mueller RP, Soffietti R, Abacioglu MU, et al.: Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of 1-3 cerebral metastases: Results of the EORTC 22952-26001 study [abstract]. J Clin Oncol 2009, 27(15s): Abstract 2008. This large trial from the EORTC was presented at the American Society of Clinical Oncology 2009 meeting and demonstrated that withholding WBRT does not affect overall survival after radiosurgery or surgical resection. WBRT does improve CNS control.
8. Aoyama H, Tago M, Kato N, et al.: Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 2007, 68:1388-1395. This is the first published randomized trial of radiosurgery with or without WBRT
9. Chang EL, Wefel JS, Hess KR, et al.: Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial. Lancet Oncol 2009, 10:1037-1044. This small randomized trial from M.D. Anderson includes the most comprehensive neurocognitive and QOL data to date on the impact of WBRT after radiosurgery
10. Li J, Bentzen SM, Renschler M, Mehta MP: Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol 2007, 25:1260-1266.
11. Hsu F, Carolan H, Nichol A, et al.: Whole brain radiotherapy with hippocampal avoidance and simultaneous integrated boost for 1-3 brain metastases: A feasibility study using volumetric modulated arc therapy. Int J Radiat Oncol Biol Phys 2010, 76:1480-1485.
12. Sturm V, Kober B, Höver KH, et al.: Stereotactic percutaneous single dose irradiation of brain metastases with a linear accelerator. Int J Radiat Oncol Biol Phys 1987, 13:279-282.
13. Shaw E, Scot C, Souhami L, et al.: Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 2000, 47:291-298.
14. Brown PD, Kee AY, Eshleman JS, Fiveash J: Adjuvant whole brain radiotherapy: Strong emotions decide but rationale studies are needed: In regard to Brown et al. (Int J Radiat Oncol Biol Phys 2008;70:1305-1309).
15. In reply to Drs. Larson and Sahgal. Int J Radiat Oncol Biol Phys 2009, 75:316-317.
16. Brown PD, Asher AL, Farace E: Adjuvant whole brain radiotherapy: Strong emotions decide but rational studies are needed. Int J Radiat Oncol Biol Phys 2008, 70:1305-1309.
17. Patchell RA, Tibbs PA, Walsh JW, et al.: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990, 322:494-500.
18. Mintz AH, Kestle J, Rathbone MP, et al.: A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996, 78:1470-1476.
19. Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al.: The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 1994, 29:711-717.
20. Patchell RA, Tibbs PA, Regine WF, et al.: Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA 1998, 280:1485-1489.
21. Siomin VE, Vogelbaum M, Kanner AA, et al.: Posterior fossa metastases: Risk of leptomeningeal disease when treated with stereotactic radiosurgery compared to surgery. J Neurooncol 2004, 67:115-121.
22. Patel AJ, Suki D, Hatiboglu MA, et al.: Factors influencing the risk of local recurrence after resection of a single brain metastasis. J Neurosurg 2009 Dec 25 (Epub ahead of print).
23. Ryken TC, McDermott M, Robinson PD, et al.: The role of steroids in the management of brain metastases: A systematic review and evidence-based clinical practice guideline. J Neurooncol 2010, 96:103-114.
24. Antonadou D, Paraskevaidis M, Sarris G, et al.: Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002, 20:3644-3650.
25. Fiveash JB, Sawrie SM, Guthrie BL, et al.: A phase II study of radiosurgery and temozolomide for patients with one to four brain metastases [abstract]. J Clin Oncol (Meeting Abstracts) 2007, 25:2048.
26. Lin NU, Diéras V, Paul D, et al.: Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009, 15:1452-1459.